Last reviewed · How we verify
Mucolytic
At a glance
| Generic name | Mucolytic |
|---|---|
| Also known as | Mucolytics |
| Sponsor | Shanghai Pulmonary Hospital, Shanghai, China |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Effect of NAC on Lung Function and CT Mucus Score (PHASE4)
- Study on the Effects and Mechanisms of Modified Ma Xing Shi Gan Decoction in Treating Acute Exacerbations of Chronic Obstructive Pulmonary Disease (NA)
- CF And Effects of Drugs Mixed Ex Vivo With Sputum for Mucolytic Treatment
- Study on the Treatment of Post-stroke Dysphagia and Stroke-associated Pneumonia With Bronchoscopy (NA)
- Development of an Interactive Digital Respiratory Game and Device and Investigation of Its Effectiveness in Children With Bronchiectasis (NA)
- Microbiological Characteristics of Biofilm on Double J Ureteral Stents After Lithotripsy. (PHASE4)
- Evaluating the Combined Effect of Oral Premedications on Inferior Alveolar Nerve Block Effectiveness (PHASE3)
- A Clinical Trial to Compare the Efficacy and Safety of 1-week Treatment of Intravenous N-acetylcysteine (NAC) 600 mg Twice Daily, Ambroxol Hydrochloride 30 mg Twice Daily and Placebo as Expectorant Therapies in Adult Chinese Patients With Respiratory Tract Diseases and Abnormal Mucus Secretions (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mucolytic CI brief — competitive landscape report
- Mucolytic updates RSS · CI watch RSS
- Shanghai Pulmonary Hospital, Shanghai, China portfolio CI